Literature DB >> 33659084

Label-free and noninvasive method for assessing the metabolic status in type 2 diabetic rats with myocardium diastolic dysfunction.

Kai Guo1,2, Junxin Wu3,2, Yawei Kong3, Li Zhou3, Wei Li1, Yiyan Fei3, Jiong Ma3,4,5,6, Lan Mi3,7.   

Abstract

This study assesses the metabolic status of rat diabetic cardiomyopathy (DCM) models. Echocardiography is used to detect the diastolic dysfunction in type 2 diabetic rats, and a lower threshold for inducible atrial fibrillation is found in type 2 diabetic rats with diastolic dysfunction compared to the control. Metabolic abnormalities are detected by status changes of reduced nicotinamide adenine dinucleotide (phosphate) (NAD(P)H), which is an essential coenzyme in cells or tissues. Fluorescence lifetime imaging microscopy (FLIM) is used to monitor changes in NAD(P)H in both myocardial tissues and blood. FLIM reveals that the protein-bound proportion of NAD(P)H in rat myocardium in the DCM group is smaller than the control group, which indicates the oxidative phosphorylation rate of the DCM group decreased. Similar results are found for blood plasma of DCM rats by the FLIM study. FLIM exhibits high potential for screening DCM as a label-free, sensitive, and noninvasive method.
© 2020 Optical Society of America under the terms of the OSA Open Access Publishing Agreement.

Entities:  

Year:  2020        PMID: 33659084      PMCID: PMC7899513          DOI: 10.1364/BOE.413347

Source DB:  PubMed          Journal:  Biomed Opt Express        ISSN: 2156-7085            Impact factor:   3.732


  2 in total

1.  Transient absorption spectroscopy and imaging of redox in muscle mitochondria.

Authors:  Erkang Wang; Luke A Whitcomb; Adam J Chicco; Jesse W Wilson
Journal:  Biomed Opt Express       Date:  2022-03-16       Impact factor: 3.562

2.  The protective effects of S14G-humanin (HNG) against streptozotocin (STZ)-induced cardiac dysfunction.

Authors:  Xiaopan Chen; Chuan Yun; Hailong Zheng; Xu Chen; Qianfei Han; Hua Pan; Yang Wang; Jianghua Zhong
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.